SiranBio Overview
- Year Founded
-
2022
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$59M
- Investors
-
10
SiranBio General Information
Description
Developer of innovative drugs designed for the nucleic acid therapy field. The company offers single-target and dual-target nucleic acid drug technology platforms and extrahepatic delivery platforms, and it has rapidly developed a pipeline of small nucleic acid drugs for intrahepatic and extrahepatic FIC and BIC, including antiviral, cardiovascular and metabolic diseases, autoimmunity, central nervous system, and other related diseases, thereby providing customers with reliable and innovative products.
Contact Information
Website
www.siranbio.comCorporate Office
- Unit 301, Building 1, Area A, Phase III Biomedical Industrial Park
- Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
- Suzhou, 215000
- China
Corporate Office
- Unit 301, Building 1, Area A, Phase III Biomedical Industrial Park
- Number 1 Xinze Road, Suzhou Industrial Park, Suzhou Area of China Pilot Free Trade Zone
- Suzhou, 215000
- China
SiranBio Timeline
SiranBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series A) | 03-Jul-2026 | $59M | Completed | Generating Revenue | ||
| 4. Early Stage VC | 24-Nov-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 25-Aug-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 06-Mar-2024 | Completed | Generating Revenue | |||
| 1. Seed Round | 14-Jun-2022 | Completed | Startup |
SiranBio Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Huatai Zijin Investment | Corporate Venture Capital | Minority | ||
| IDG Capital | Venture Capital | Minority | ||
| SDIC Capital Management | Growth/Expansion | Minority | ||
| Sunshine Ronghui Capital Investment Management | Corporate Venture Capital | Minority | ||
| Suzhou Angel Fund of Funds | Government | Minority |
SiranBio FAQs
-
When was SiranBio founded?
SiranBio was founded in 2022.
-
Where is SiranBio headquartered?
SiranBio is headquartered in Suzhou, China.
-
What industry is SiranBio in?
SiranBio’s primary industry is Drug Discovery.
-
Is SiranBio a private or public company?
SiranBio is a Private company.
-
What is SiranBio’s current revenue?
The current revenue for SiranBio is .
-
How much funding has SiranBio raised over time?
SiranBio has raised $59M.
-
Who are SiranBio’s investors?
Huatai Zijin Investment, IDG Capital, SDIC Capital Management, Sunshine Ronghui Capital Investment Management, and Suzhou Angel Fund of Funds are 5 of 10 investors who have invested in SiranBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process